Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG

Abstract

The aim of this study was to describe the baseline demographic and clinical characteristics as well as the functional status of a prospective cohort of patients with rheumatic diseases assisted by the Brazilian Public Health System (SUS). Data for 302 patients receiving tumor necrosis factor α inhibitors (anti-TNF agents) was collected through a standard form. Among patients, 229 (75.8%) were female and 155 (51.3%) were Caucasian; the mean age was 50.3 ± 12.8 years, and the mean disease duration was 9.9 ± 8.7 years. Among them 214 patients (70.9%) received adalimumab, 72 (23.8%) etanercept, and 16 (5.3%) infliximab. Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) was 1.37 ± 0.67 for all participants. Poor functional response was associated with female gender, married patients and with a score of < 0.6 on the EuroQoL-5 dimensions (EQ-5D). Significant correlation was found between the HAQ-DI values, disease activity and quality of life (QOL). The results obtained in this study contribute to a better understanding of the clinical and demographic characteristics of patients with rheumatic diseases at the beginning of anti-TNF-agent treatment by SUS. Furthermore, our findings are consistent with another Brazilian and foreign cross-sectional investigations. This knowledge can be of great importance for further studies evaluating the effectiveness of biological agents, as well as, to contribute to improve the well-being of the patients with rheumatic diseases.

Qualidade De Vida De Pacientes Diagnosticados Com Espondilite Anquilosante: Uma Revisão Integrativa

“…Do total de artigos, 12 (N1, N2, N3, N6, N7, N9, N13, N14, N15, N16, N17, N19) possibilitaram a análise da população conforme o sexo, observandose maior prevalência do sexo masculino (KJEKEN et al, 2013;CONNOLLY;FITZPATRICK;O'SHEA, 2019;ALAMINO et al, 2011;LAW et al, 2018;WEBERS et al, 2016;DURCAN et al, 2012;FIGUEREDO et al, 2014;AZEVEDO et al, 2010;AZEVEDO et al, 2016;OLIVEIRA JUNIOR et al, 2015;AYDIN et al, 2015;BAE et al, 2019). Apesar de alguns dos estudos, como N13 e N16 (FIGUEREDO et al, 2014;OLIVEIRA JÚNIOR et al, 2015), N16 apontou que homens apresentam melhor status funcional que mulheres, correlacionando melhores níveis de funcionalidade (HAQ-DI) a melhores índices de qualidade de vida e de atividade da doença (BASDAI e CDAI) (OLIVEIRA JÚNIOR et al, 2015).…”

“…Observou-se o predomínio no uso das seguintes classes de medicamentos: Inibidores do Fator de Necrose Tumoral (TNF-i), os Medicamentos Modificadores do Curso da Doença (MMCD's) e os antiinflamatórios não esteroides (AINEs) (OLIVEIRA JUNIOR et al, 2015;PARK et al, 2019).…”

Variações Anatômicas: o avanço da ciência no Brasil

“…Outra abordagem igualmente importante é a fisioterapia que visa reduzir os comprometimentos de mobilidade e ameniza os sintomas.Durante anos, a principal medicação utilizada na EA foram os AINEs, porém, esses fármacos não eram tão efetivos contra a EA, se comparada a eficácia em outras espondiloartrites. Atualmente, recomenda-se a administração conjunta de AINEs e anti-TNF, o que trouxeram evidências de melhora dos sintomas(PARK et al 2019). O uso de AINEs (como causar graves efeitos gastrointestinais ou cardiovasculares.…”